Xiao Huang
Directeur/Membre du Conseil chez CUTIA THERAPEUTICS
Profil
Xiao Huang has held various director positions at CBMG Holding AB, Shanghai Yunfeng Investment Management Co. Ltd., Sironax Ltd., and Cutia Therapeutics (Shanghai) Co., Ltd.
He is currently a Director at CBMG Holding AB and a Managing Director at Shanghai Yunfeng Investment Management Co. Ltd.
Additionally, he serves as a Non-Executive Director at Cutia Therapeutics and MicroPort Cardiac Rhythm Management International Ltd.
Dr. Huang obtained a doctorate degree from Yale University in 2012 and an undergraduate degree from Tsinghua University in 2007.
Postes actifs de Xiao Huang
| Sociétés | Poste | Début |
|---|---|---|
| CUTIA THERAPEUTICS | Directeur/Membre du Conseil | 26/08/2020 |
Cutia Therapeutics (Shanghai) Co., Ltd.
 Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Directeur/Membre du Conseil | - |
Shanghai Yunfeng Investment Management Co. Ltd.
 Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/05/2015 |
Sironax Ltd.
 Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Directeur/Membre du Conseil | - |
MicroPort Cardiac Rhythm Management International Ltd.
 MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | 28/04/2020 |
| CBMG Holding AB | Directeur/Membre du Conseil | 01/02/2021 |
Formation de Xiao Huang
| Yale University | Doctorate Degree |
| Tsinghua University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CUTIA THERAPEUTICS | Health Technology |
| Entreprise privées | 5 |
|---|---|
| CBMG Holding AB | |
Shanghai Yunfeng Investment Management Co. Ltd.
Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Health Technology |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Finance |
